echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > All win! Aibowei and "tough guy" Bi reach a settlement on xiumeile patent

    All win! Aibowei and "tough guy" Bi reach a settlement on xiumeile patent

    • Last Update: 2019-05-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The US biotech giant, Abercrombie, recently announced that it has reached a settlement with blinger Ingelheim (BI) over the patent lawsuit of Humira (adamumumab) According to the agreement, eberway has granted Bi a non exclusive right to the intellectual property related to sumerial in the United States, and the latter's adamutumab bio generic drug can be launched on the market on July 1, 2023 Bi will pay the royalties to abwi, and abwi is not required to pay any form of payment to bi Stimulated by the favorable news, Aberdeen shares rose 2% Laura Schumacher, the company's vice president of external affairs and chief legal officer, said the settlement settled all patent lawsuits related to sumac in the United States and provided a way for another bio imitator to enter the United States Before that, Alberto has reached a settlement agreement with eight pharmaceutical companies, namely: Amgen, Samsung bioepis / MSD, mylan, Sandoz, fresenyuskabi, momenta, Pfizer, and coherus biosciences Under the terms of the agreement, these companies' adamumumab biosimilars can be launched in the United States at different times in 2023, and will not be advanced due to the listing of other authorized products Therefore, the settlement also means that Aberdeen has achieved a winning streak in defending the franchise of xiumeile Bi is a tough guy when it comes to patent litigation with Aberdeen Prior to this, Bi has refused to reach a settlement with, and insisted that eberver intervened in the listing of adamutumab bio generic drugs through unreasonable means such as patent superposition and non invention patents In November last year, Bi even announced that it would abandon the development of biosimilars in markets outside the United States and focus on the U.S market At that time, a spokesperson vowed that it would definitely launch its adamuzumab biopharmaceutical cyltezo in the U.S by 2023 Now it looks like the face is really slapping The sales volume of the world's best-selling drugs in 2018 is nearly 20 billion US dollars Humira is a super heavyweight product of Albright and the world's best-selling drug In 2018, the global sales volume reached 19.936 billion US dollars, including the net income of the US market of 13.685 billion US dollars The patent protection of Humira Europe has expired in October 2018 Amgevita, imraldi, hyrimoz and Hulio have been listed in Europe In the U.S., three adalimumab biosimilars have been approved - amjevita (September 2016), cyltezo (August 2017), hyrimoz (October 2018) In the first quarter of 2019, xiumeile's net income was $4.446 billion, down 5.6% year-on-year, including $3.215 billion in the U.S market, up 7.1%; while in the international market, due to the competition of bio generic drugs, the sales of Humira dropped by 27.9% to $1.231 billion However, Sumeria's revenue growth in the U.S market is not due to an increase in prescription volumes, but to higher prices Drug pricing is still a key sensitive topic in the United States Therefore, the performance of Sumeria is still to be seen before the US patent cliff But there is no doubt that it has become more and more difficult for him to gain income growth in this cash cow However, the company will launch new products in immunology, among which skyrizi, a key product, has recently been approved by us and European regulatory agencies for the treatment of plaque psoriasis Upadacitinib, another oral Jak1 inhibitor, is currently under the FDA's prior review for the treatment of rheumatoid arthritis, and is expected to be approved in August this year Skyrizi's sales in 2023 are expected to reach US $5 billion, and upadacitinib's sales in the same period are expected to reach US $2.2 billion The two drugs are expected to make up for the losses caused by the impact of adamutumab bio generic drugs in the US market However, some analysts pointed out that the market competition for these two drugs is extremely fierce, and achieving the peak target is not a small challenge for Aberdeen Oncology has become one of the key therapeutic fields of Albuquerque According to the performance report of 2019q1, the global net income of its oncology product portfolio was USD 1.173 billion, up 42.8%; among them, the first quarter net income of BTK inhibitor imbruvica was USD 1.02billion, up 34%; the first quarter net income of Bcl-2 inhibitor venclexta was USD 151 million, up more than 100% The two drugs were developed in cooperation with Johnson & Johnson and Roche respectively At present, they are in large-scale clinical projects to explore the therapeutic potential for various types of hematological malignancies Reference sources: 1 Abbvie resolves Humira? (adalimumab) U.S patient detention with Boehringer Ingelheim 2 Boehringer Ingelheim flies the white flag as last holdout surrenders in war over a $20b abbvie gold mine 3 Boehringer buckles in abbvie pattern fit, saving Humira from biosimis until 2023
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.